XTANT MEDICAL HOLDINGS INC (XTNT)
US98420P3082 - Common Stock
XTNT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. XTNT may be in some trouble as it scores bad on both profitability and health. XTNT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year XTNT has reported negative net income.
XTNT had a negative operating cash flow in the past year.
XTNT had negative earnings in 4 of the past 5 years.
XTNT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -3.49%, XTNT is in the better half of the industry, outperforming 65.08% of the companies in the same industry.
XTNT has a Return On Equity of -7.41%. This is in the better half of the industry: XTNT outperforms 65.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.49% | ||
| ROE | -7.41% | ||
| ROIC | N/A |
ROA(3y)-7.41%
ROA(5y)-11.65%
ROE(3y)-13.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
XTNT has a Gross Margin of 61.61%. This is in the better half of the industry: XTNT outperforms 61.90% of its industry peers.
XTNT's Gross Margin has been stable in the last couple of years.
XTNT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.97%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
XTNT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XTNT has been increased compared to 1 year ago.
Compared to 5 years ago, XTNT has more shares outstanding
XTNT has a better debt/assets ratio than last year.
2.2 Solvency
XTNT has an Altman-Z score of -1.61. This is a bad value and indicates that XTNT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.61, XTNT is not doing good in the industry: 61.38% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.49 indicates that XTNT is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.49, XTNT is not doing good in the industry: 62.43% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.61 |
ROIC/WACCN/A
WACC9.9%
2.3 Liquidity
A Current Ratio of 2.44 indicates that XTNT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.44, XTNT is doing worse than 60.85% of the companies in the same industry.
XTNT has a Quick Ratio of 1.01. This is a normal value and indicates that XTNT is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of XTNT (1.01) is worse than 82.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.44 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
XTNT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.78%, which is quite impressive.
The Revenue has grown by 63.37% in the past year. This is a very strong growth!
Measured over the past years, XTNT shows a small growth in Revenue. The Revenue has been growing by 4.81% on average per year.
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)63.37%
Revenue growth 3Y19.62%
Revenue growth 5Y4.81%
Sales Q2Q%48%
3.2 Future
The Earnings Per Share is expected to grow by 16398600.00% on average over the next years. This is a very strong growth
XTNT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.40% yearly.
EPS Next Y-1249478680617671200%
EPS Next 2Y-3834025093.41%
EPS Next 3Y16398600%
EPS Next 5YN/A
Revenue Next Year31.92%
Revenue Next 2Y22.4%
Revenue Next 3Y22.4%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for XTNT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XTNT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as XTNT's earnings are expected to grow with 16398600.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3834025093.41%
EPS Next 3Y16398600%
5. Dividend
5.1 Amount
No dividends for XTNT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
XTANT MEDICAL HOLDINGS INC
NYSEARCA:XTNT (9/6/2024, 8:04:00 PM)
0.5651
+0 (+0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap73.62M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.49% | ||
| ROE | -7.41% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.61% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.44 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-1249478680617671200%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)63.37%
Revenue growth 3Y19.62%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y